GH Research (NASDAQ:GHRS – Get Free Report) had its target price lowered by HC Wainwright from $65.00 to $55.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s price objective would suggest a potential upside of 201.37% from the company’s previous close.
Other research analysts also recently issued reports about the stock. Needham & Company LLC raised their price objective on shares of GH Research from $32.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wells Fargo & Company assumed coverage on shares of GH Research in a report on Monday, July 27th. They set an “overweight” rating and a $44.00 target price on the stock. Wall Street Zen upgraded GH Research from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Stifel Nicolaus set a $38.00 target price on GH Research in a research report on Friday, November 13th. Finally, Zacks Research raised GH Research from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.00.
View Our Latest Research Report on GHRS
GH Research Stock Down 0.1%
GH Research (NASDAQ:GHRS – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.13. As a group, equities research analysts anticipate that GH Research will post -1.20 EPS for the current year.
Institutional Investors Weigh In On GH Research
A number of institutional investors and hedge funds have recently modified their holdings of GHRS. Royal Bank of Canada boosted its position in shares of GH Research by 43.1% in the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock valued at $36,000 after acquiring an additional 780 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in GH Research during the 3rd quarter worth approximately $82,000. Bellevue Group AG bought a new stake in GH Research during the 3rd quarter worth approximately $109,000. Farther Finance Advisors LLC lifted its stake in GH Research by 9,720.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock worth $231,000 after purchasing an additional 9,720 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in GH Research in the 1st quarter worth approximately $290,000. 56.90% of the stock is owned by hedge funds and other institutional investors.
About GH Research
GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.
Further Reading
- Five stocks we like better than GH Research
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
